A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in
combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this
combination in relapsed/refractory Epstein-Barr Virus Associated Lymphoma (EBV+
lymphomas).
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03397706.
Locations matching your search criteria
United States
Georgia
Atlanta
Emory University Hospital/Winship Cancer InstituteStatus: Active
Name Not Available
The purpose of this study is to determine whether VRx-3996 in combination with
valganciclovir is safe, determine the side effect profile, and to determine whether this
therapy may help patients with EBV-related lymphomas. The study has two phases. Goals of
the first phase include determining a safe and tolerable dose that can be administered in
phase 2. Goals of the second phase include further evaluating the safety and tolerability
of VRx-3996 in combination with valganciclovir, evaluating how the drugs are metabolized
in the body, evaluating response rates and other exploratory objectives that will help
the researchers evaluate how these drugs work in the body. Participants will receive
daily oral doses of the two study drugs and will have multiple study visits where they
will have blood collected, physical examinations, and other medical monitoring. Following
completion of the Ph2, the study will enroll additional patients into a Tablet
Pharmacokinetic (PK) cohort to investigate the PK parameters of the tablet formulation.
Lead OrganizationViracta Therapeutics, Inc.
